Article

Consider artificial cornea in patients with multiple graft rejections

The use of an artificial cornea in patients who have experienced multiple immunologic graft rejections is more likely to result in good-quality vision than is performing another corneal transplant, said Michael W. Belin, MD, Albany Medical College, Albany, NY.

The use of an artificial cornea in patients who have experienced multiple immunologic graft rejections is more likely to result in good-quality vision than is performing another corneal transplant, said Michael W. Belin, MD, Albany Medical College, Albany, NY.

He provided an update of results of an ongoing international, multicenter study of a proprietary device (Boston Keratoprosthesis, Massachusetts Eye & Ear Infirmary) involving 250 eyes. Dr. Belin said that he has been using the device for about 5 years.

"The major advantage is that, when we look at the survivability of a graft after a second failed graft, the rate of retention of that transplant clarity drops significantly," he said. "While the success rate on primary grafts is very high, with failure at maybe 10% or less, once we get to two prior grafts, the rejection rate increases to nearly 40%.

"Statistically, patients do much better with a keratoprosthesis than a third, fourth, or fifth transplant, assuming that their cornea is relatively non-vascularized and that they have a reasonable ocular surface," he said.

Visual rehabilitation is faster with the device than with repeated keratoplasty, he added, because astigmatism is not associated with it.

Potential drawbacks to implanting an artificial cornea are similar to those associated with any transplant, Dr. Belin said.

"Any transplant, particularly repeat transplants, have an increased risk of inducing glaucoma or a pressure problem, and it's conceivable that the donor rim can melt as a transplant would melt," he said. "But the prosthesis is very well-tolerated by the eye."

The multicenter study has demonstrated a graft survival rate of more than 95%, Dr. Belin said, "and if we look at the subset of just patients with immunologic graft rejection, not ocular surface disease, the rate increases to about 98%."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.